Stage 4 lung cancer: complete response to chemoimmunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 20 duplication with PD-L1 TPS 70%; P40/CK5/6 positive squamous markers; Ki-67 60%.

Metastatic Site: right adrenal gland; possible adjacent…

As of May 7, 2024, CT follow-up showed no evidence of disease after chemoimmunotherapy, conversion surgery with pathologic complete response, and pembrolizumab maintenance.

PubMed CentralRead more →

ROS1-Positive Stage III Lung Adenocarcinoma With Pathologic Complete Response

Patient Info: Anonymized, male, 40s | Stage III

Biomarkers: ROS1 fusion-positive

Surgery found no residual cancer cells or involved lymph nodes, and no recurrence was detected during 10 months of crizotinib treatment and follow-up.

PubMed CentralRead more →

Stage IV lung cancer: brain metastasis complete response after chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS-mutated; BRG-1 partial loss; PD-L1 TPS 5%; CPS 20

Metastatic Site: brain (right cerebellar hemisphere)

The right cerebellar brain metastasis completely resolved and chest CT showed only postsurgical changes after carrelizumab plus paclitaxel/carboplatin; immune-mediated adrenal insufficiency improved with systemic glucocorticoids.

PubMed CentralRead more →

ROS1-Positive Stage III Pulmonary Sarcomatoid Carcinoma With Complete Pathologic Response

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: ROS1 rearrangement; TP53 mutation; PD-L1 TPS 0%

No recurrence was seen for more than 30 months after surgery following a complete pathologic response.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response to Neoadjuvant Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PIK3CA mutation; TP53 mutation; PD-L1 TPS 5%

No recurrence was detected for more than 29 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response and No Recurrence

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: NRAS mutation; TP53 mutation; PD-L1 TPS 60%

No recurrence was detected for more than 27 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma Treated With Neoadjuvant Immunochemotherapy and Surgery

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 mutation; PD-L1 TPS 40%

No recurrence was detected for more than 30 months after surgery.

PubMed CentralRead more →

Stage 3C lung cancer: complete remission on immunotherapy and chemotherapy

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: EGFR wild-type; ALK rearrangement not detected; PD-L1 <1%

Complete tumor remission with no recurrence more than 6 months after durvalumab, tremelimumab, carboplatin, and nab-paclitaxel for Stage IIIC driver-negative NSCLC, despite severe immune, infectious, cardiac, renal, and fistula complications that later resolved or stabilized.

PubMed CentralRead more →

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed CentralRead more →

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed CentralRead more →

Primary Lung Cancer That Spread to Both Breasts and the Adrenal Gland

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: PD-L1 negative; EGFR, ALK, ROS1, RET, MET exon 14, NTRK and BRAF wild type

Metastatic Site: both breasts, subcutaneous tissue, adrenal gland

After the lung origin was established, she was in good general condition and asymptomatic while first-line systemic therapy was being planned.

PubMed CentralRead more →

Lung squamous cell carcinoma spreading to bone and intestine

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 positive in almost all tumor cells

Metastatic Site: bone (left femur), intestine, abdomen

Despite chemotherapy, immunotherapy and radiation, the lung cancer progressed with intestinal and extensive abdominal metastases, cachexia and gastrointestinal bleeding. Palliative care was planned, but he chose discharge and received no further treatment.

PubMed CentralRead more →

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD AndersonRead more →

Stage 4 lung cancer: complete response to chemo-immunotherapy combo

Patient Info: Anonymized, Male, 40s | Stage IV

Metastatic Site: right hilar lymph nodes, mediastinal lymph nodes

Stage IVA lung squamous cell carcinoma achieved complete response at 12 months. Pembrolizumab was stopped after immune-related RS3PE and likely colitis; 8 months after glucocorticoid initiation, there was no relapse of lung cancer or RS3PE.

PubMed CentralRead more →

Stage IV lung squamous cell cancer complicated by adrenal insufficiency during immunotherapy

Patient Info: Anonymized, male, 50s | Stage IV

Mediastinal and hilar lymph nodes improved on treatment. Immunotherapy remained paused because of adrenal insufficiency, and updated follow-up found no recurrence or additional metastasis.

PubMed CentralRead more →

Stage IV lung squamous cell cancer with bone metastasis and immunotherapy-related adrenal insufficiency

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: rib/bone

After earlier progression with rib/bone destruction, the latest chest CT showed lung lesions similar to prior imaging. Tislelizumab remained paused because of adrenal insufficiency.

PubMed CentralRead more →

Stage III lung squamous cell cancer treated with immunotherapy, surgery and chemotherapy

Patient Info: Anonymized, male, 50s | Stage III

After surgery and systemic treatment, updated follow-up found no recurrence or metastasis. Tislelizumab remained stopped after recurrent adrenal insufficiency.

PubMed CentralRead more →

Treatment-related lung injury during therapy for Stage IV squamous lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

A 63-year-old man with Stage IV squamous lung cancer developed interstitial lung disease soon after starting chemotherapy and immunotherapy, with respiratory findings improving after steroid treatment.

PubMed CentralRead more →

Stage IV pulmonary mucoepidermoid carcinoma with an ALK fusion responding to targeted therapy

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EML4-ALK fusion; PD-L1 <1%

Metastatic Site: liver

By December 2023, oral ALK-targeted therapy was ongoing with a partial response, improved symptoms, weight gain, and marked shrinkage of lung and metastatic disease.

PubMed CentralRead more →

SMARCA4-deficient undifferentiated lung cancer with pleural disease and later spinal metastasis

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: BRCA1 p.S1796 variant; TP53 p.; tumor mutational burden 12.6

Metastatic Site: spine

After chemotherapy and one cycle of nivolumab, a new 4.5 cm spinal metastasis caused cord compression and required surgery; further outpatient treatment was planned.

PubMed CentralRead more →

Stage II lung adenocarcinoma with severe atezolizumab-related myocarditis after surgery

Patient Info: Anonymized, female, 40s | Stage II

Biomarkers: PD-L1 TPS 50%

More than 1 year after atezolizumab was discontinued, there was no recurrence of the lung cancer.

PubMed CentralRead more →

Stage III squamous lung cancer controlled during treatment while a second pancreatic cancer developed

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: KRAS exon 2 mutation

She died in March 2022. Her Stage III lung cancer had remained controlled for about 18 months, while a separate pancreatic cancer developed and progressed.

PubMed CentralRead more →

Lung squamous cell cancer treated with chemotherapy and nivolumab alongside IgG4-related disease

Patient Info: Anonymized, male, 70+

Biomarkers: PD-L1 TPS 65%

Nivolumab was stopped after disease progression, and he died from progressive lung cancer 17 months later.

PubMed CentralRead more →

First reported case of a severe immune reaction (cytokine release syndrome) from tislelizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: pleura (malignant pleural effusion)

The cytokine release syndrome initially improved with high-dose steroids, but he developed severe ventilator-associated pneumonia during the steroid taper and died.

PubMed CentralRead more →